Name: Satellite Symposium: Ask the Expert: An Open Forum on Hodgkin Lymphoma
Start: 2016-10-25T07:30
End: 2016-10-25T08:30
Location: Großer Saal

07:30 – 08:30

Room: Großer Saal

Satellite Symposium (by Bristol-Myers Squibb) Ask the Expert: An Open Forum on Hodgkin Lymphoma

Philippe Armand

07:30–07:50
Panelists
- Graham Collins
- Catherine Diefenbach
- Craig H. Moskowitz
- Vincent Ribrag

08:30 – 10:00

Room: Großer Saal

Scientific Session Pediatric HL

Christine Mauz-Körholz
Nelson Spector

08:30–08:50
Interim results of EuroNet-PHL-C1
- Judith Landman-Parker
08:50–09:10
Targeted agents in pediatric HL
- Monika Metzger
09:10–09:30
COG / ECOG: AYA HL
- Kara Kelly
09:30–09:40
- Abstract Talk
Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/ A12707)
- Stephen Daw
09:40–09:50
- Abstract Talk
Phase III ABC study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children's Oncology Group
- Kara Kelly
09:50–10:00
- Abstract Talk
Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis
- Andrew Evens

10:30 – 12:00

Room: Großer Saal

Scientific Session Advanced Stages

Volker Diehl
Massimo Federico

10:30–11:10
Debate: PET-guided ABVD versus old school BEACOPP
- Peter Borchmann
- Anton Hagenbeek
- Peter Johnson
11:10–11:30
Perspectives in advanced HL
- Pauline Brice
11:30–11:40
- Abstract Talk
BEACOPPescalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials
- Bastian von Tresckow
11:40–11:50
- Abstract Talk
Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials
- Marc André
11:50–12:00
- Abstract Talk
Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging,
- Jonathan Friedberg

12:15 – 13:00

Room: Großer Saal

Satellite Symposium (by Roche Pharma AG) Classification of New Therapeutic Options for CLL and Follicular NHL

Kai Hübel

12:15–12:35
Chronic Lymphocytic Leukemia
- Clemens Wendtner
12:35–13:00
Relapsed Follicular Non-Hodgkin Lymphoma
- Kai Hübel

13:00 – 13:45

Room: Kleiner Saal

Main Program Poster Walk

14:00 – 15:30

Room: Großer Saal

Scientific Session Relapsed HL

Pauline Brice
Andreas Engert

14:00–14:20
Brentuximab vedotin in relapsed HL
- Craig H. Moskowitz
14:20–14:40
Clinical results with anti-PD(L)1 antibodies in HL
- Philippe Armand
14:40–15:00
Role of allo-Tx in the PD1 era
- Franck Morschhauser
15:00–15:10
- Abstract Talk
CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation
- Pier Luigi Zinzani
15:10–15:20
- Abstract Talk
Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study
- Craig H. Moskowitz
15:20–15:30
- Abstract Talk
TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study
- Anton Hagenbeek

16:00 – 17:30

Room: Großer Saal

Scientific Session Survivorship

Peter Borchmann
Flora van Leeuwen

16:00–16:20
Fatigue
- Steffanie Kreissl
16:20–16:40
Survivorship surveillance
- Alexander Fosså
16:40–17:00
Second malignancies
- Flora van Leeuwen
17:00–17:10
- Abstract Talk
Patient preferences – survey of HL survivors on treatment associated burdens and side effects
- Carolin Bürkle
17:10–17:20
- Abstract Talk
Change in peripheral blood lymphocyte telomere length in relation to mortality and morbidity in Hodgkin Lymphoma patients
- Radhia M'kacher
17:20–17:30
- Abstract Talk
The impact of treatment type and age on ovarian toxicity in the RATHL study
- RA Anderson

17:45

Room: Großer Saal

Scientific Session Closing Remarks

Andreas Engert

Program: Tuesday (25.10.2016)

07:30 – 08:30

Satellite Symposium (by Bristol-Myers Squibb) Ask the Expert: An Open Forum on Hodgkin Lymphoma

Panelists

08:30 – 10:00

Scientific Session Pediatric HL

Interim results of EuroNet-PHL-C1

Targeted agents in pediatric HL

COG / ECOG: AYA HL

Whole body functional and anatomical MRI: accuracy in staging and treatment response monitoring in childhood and adolescent Hodgkin’s Lymphoma compared to conventional multimodality imaging (CRUK C23580/ A12707)

Phase III ABC study of response adapted therapy for the treatment of children with newly diagnosed very high risk Hodgkin Lymphoma (Stages IIIB/IVB) (AHOD0831): a report from the Children's Oncology Group

Outcomes in adolescents and young adults (AYA) with Hodgkin Lymphoma (HL) treated on US cooperative group protocols: an adult intergroup (E2496) and Children’s Oncology Group (COG AHOD0031) comparative analysis

10:30 – 12:00

Scientific Session Advanced Stages

Debate: PET-guided ABVD versus old school BEACOPP

Perspectives in advanced HL

BEACOPPescalated followed by radiotherapy of initial bulk or residual disease in advanced-stage Hodgkin Lymphoma: long-term follow-up of the GHSG HD9 and HD12 trials

Overall survival (OS) impact of BEACOPP versus ABVD in advanced Hodgkin Lymphoma: a pooled analysis of 4 randomized trials

Long-term follow-up of SWOG S0816: response-adapted therapy of advanced stage Hodgkin Lymphoma using early interim FDG-PET imaging,

12:15 – 13:00

Satellite Symposium (by Roche Pharma AG) Classification of New Therapeutic Options for CLL and Follicular NHL

Chronic Lymphocytic Leukemia

Relapsed Follicular Non-Hodgkin Lymphoma

13:00 – 13:45

Main Program Poster Walk

14:00 – 15:30

Scientific Session Relapsed HL

Brentuximab vedotin in relapsed HL

Clinical results with anti-PD(L)1 antibodies in HL

Role of allo-Tx in the PD1 era

CheckMate 205 cohort C: Nivolumab in patients with classical Hodgkin Lymphoma after prior Brentuximab Vedotin and autologous hematopoietic stem cell transplantation

Pembrolizumab for relapsed / refractory classical Hodgkin Lymphoma (R / R cHL): multicohort, phase 2 KEYNOTE-087 study

TRANSPLANT BRaVE: combining Brentuximab Vedotin with DHAP as salvage treatment in relapsed / refractory Hodgkin Lymphoma (HL). A phase 1 dose- escalation study

16:00 – 17:30

Scientific Session Survivorship

Fatigue

Survivorship surveillance

Second malignancies

Patient preferences – survey of HL survivors on treatment associated burdens and side effects

Change in peripheral blood lymphocyte telomere length in relation to mortality and morbidity in Hodgkin Lymphoma patients

The impact of treatment type and age on ovarian toxicity in the RATHL study

17:45

Scientific Session Closing Remarks

Archive